{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-26-054711","form_type":"8-K","ticker":"QTTB","cik":"0001661998","company_name":"Q32 Bio Inc.","filed_at":"2026-02-17T23:59:59+00:00","discovered_at":"2026-05-14T18:02:35.799212+00:00","generated_at":"2026-05-16T02:26:49.106410+00:00","sec_items":["1.01","8.01","9.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"Q32 Bio raises $10.5M in registered direct offering to fund bempikibart trials","bullets":["Gross proceeds of ~$10.5M from 1,666,679 common shares and pre-funded warrants for 1,025,654 shares at $3.90/share.","Offering price equals Feb 13 closing price; pre-funded warrants exercisable at $0.0001/share.","Net proceeds for working capital, including advancing bempikibart for alopecia areata into future trials.","Closing expected Feb 18, 2026; led by new institutional investor with participation from existing investor."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-26-054711","json":"https://secwatch.observer/filing/0001193125-26-054711.json","markdown":"https://secwatch.observer/filing/0001193125-26-054711.md","text":"https://secwatch.observer/filing/0001193125-26-054711.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1661998/000119312526054711/0001193125-26-054711-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1661998/000119312526054711/d113308d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-16T02:26:49.106410+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"93b3a6557b78e4479deef0bc03609e5da85ae02a","claim":"Q32 Bio Inc. entered into Purchase Agreement with certain institutional investors valued at approximately $10.5 million (effective 2026-02-17).","evidence_excerpt":"On February 17, 2026, Q32 Bio Inc. (the “Company”) entered into a securities purchase agreement (the “Purchase Agreement”) with certain institutional investors relating to the issuance and sale of (i) 1,666,679 shares (the “Shares”) of the Company’s common stock, par value $0.0001 per share (the “Common Stock”), at a purchase price of $3.90 per share, and (ii) pre-funded warrants to purchase 1,025,654 shares of Common Stock (the “Pre-Funded Warrants”), to such investors in a registered direct offering (the “Offering”).","evidence_source":"SEC 8-K Item 1.01/1.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1661998/000119312526054711/0001193125-26-054711-index.htm","confidence":0.9,"family_label":"Material Agreements","details":[{"label":"Action","value":"entry"},{"label":"Agreement","value":"equity purchase"},{"label":"Counterparty","value":"certain institutional investors"},{"label":"Value","value":"approximately $10.5 million"},{"label":"Effective","value":"2026-02-17"}]}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}